Epithelioid Sarcoma: Opportunities for Biology-Driven Targeted Therapy

Enzinger, 1970, Epitheloid sarcoma. A sarcoma simulating a granuloma or a carcinoma, Cancer, 26, 1029, 10.1002/1097-0142(197011)26:51029::AID-CNCR28202605103.0.CO;2-R

Jawad, 2009, Prognostic factors for survival in patients with epithelioid sarcoma: 441 cases from the SEER database, Clin Orthop Relat Res, 467, 2939, 10.1007/s11999-009-0749-2

Casanova, 2006, Epithelioid sarcoma in children and adolescents: a report from the Italian Soft Tissue Sarcoma Committee, Cancer, 106, 708, 10.1002/cncr.21630

Rakheja, 2005, “Proximal-type” and classic epithelioid sarcomas represent a clinicopathologic continuum: case report, Pediatr Dev Pathol, 8, 105, 10.1007/s10024-005-0148-y

Armah, 2009, Epithelioid sarcoma, Arch Pathol Lab Med, 133, 814, 10.1043/1543-2165-133.5.814

Guillou, 1997, “Proximal-type” epithelioid sarcoma, a distinctive aggressive neoplasm showing rhabdoid features. Clinicopathologic, immunohistochemical, and ultrastructural study of a series, Am J Surg Pathol, 21, 130, 10.1097/00000478-199702000-00002

Fisher, 2006, Epithelioid sarcoma of Enzinger, Adv Anat Pathol, 13, 114, 10.1097/00125480-200605000-00002

Errani, 2011, A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites, Genes Chromosomes Cancer, 50, 644, 10.1002/gcc.20886

Chbani, 2009, Epithelioid sarcoma: a clinicopathologic and immunohistochemical analysis of 106 cases from the French sarcoma group, Am J Clin Pathol, 131, 222, 10.1309/AJCPU98ABIPVJAIV

Brennan, 2013, Management of Soft Tissue Sarcoma, 10.1007/978-1-4614-5004-7

Chase, 1985, Epithelioid sarcoma. Diagnosis, prognostic indicators, and treatment, Am J Surg Pathol, 9, 241, 10.1097/00000478-198504000-00001

Ross, 1997, Epithelioid sarcoma: clinical behavior and prognostic factors of survival, Ann Surg Oncol, 4, 491, 10.1007/BF02303673

Callister, 2001, Epithelioid sarcoma: results of conservative surgery and radiotherapy, Int J Radiat Oncol Biol Phys, 51, 384, 10.1016/S0360-3016(01)01646-7

Wolf, 2008, Epithelioid sarcoma: the University of Washington experience, Am J Surg, 196, 407, 10.1016/j.amjsurg.2007.07.029

Shimm, 1983, Radiation therapy of epithelioid sarcoma, Cancer, 52, 1022, 10.1002/1097-0142(19830915)52:61022::AID-CNCR28205206163.0.CO;2-I

Livi, 2003, Treatment of epithelioid sarcoma at the Royal Marsden Hospital, Sarcoma, 7, 149, 10.1080/13577140310001644760

Hasegawa, 2001, Proximal-type epithelioid sarcoma: a clinicopathologic study of 20 cases, Mod Pathol, 14, 655, 10.1038/modpathol.3880368

Baratti, 2007, Epithelioid sarcoma: prognostic factors and survival in a series of patients treated at a single institution, Ann Surg Oncol, 14, 3542, 10.1245/s10434-007-9628-9

Levy, 2014, Epithelioid sarcoma: need for a multimodal approach to maximize the chances of curative conservative treatment, Ann Surg Oncol, 21, 269, 10.1245/s10434-013-3247-4

Jones, 2012, Role of palliative chemotherapy in advanced epithelioid sarcoma, Am J Clin Oncol, 35, 351, 10.1097/COC.0b013e3182118cf7

Pink, 2014, Gemcitabine and docetaxel for epithelioid sarcoma: results from a retrospective, multi-institutional analysis, Oncology, 87, 95, 10.1159/000362602

Tariq, 2012, A case report of complete remission of pulmonary metastases from epithelioid sarcoma to navelbine chemotherapy, Am J Ther, 19, e95, 10.1097/MJT.0b013e3181e70a50

Piovesan, 2009, Proximal-type epithelioid sarcomas: a retrospective analyses of 31 patients

Cordoba, 1994, A new cytogenetic finding in an epithelioid sarcoma, t(8;22)(q22;q11), Cancer Genet Cytogenet, 72, 151, 10.1016/0165-4608(94)90132-5

Dal Cin, 1999, Epithelioid sarcoma of the proximal type with complex karyotype including i(8q), Cancer Genet Cytogenet, 114, 80

Iwasaki, 1996, Epithelioid sarcoma with an 18q aberration, Cancer Genet Cytogenet, 91, 46, 10.1016/S0165-4608(95)00315-0

Molenaar, 1989, Epithelioid sarcoma or malignant rhabdoid tumor of soft tissue? Epithelioid immunophenotype and rhabdoid karyotype, Hum Pathol, 20, 347, 10.1016/0046-8177(89)90044-0

Sonobe, 1997, Involvement of 8q, 22q, and monosomy 21 in an epithelioid sarcoma, Cancer Genet Cytogenet, 96, 178

Debiec Rychter, 2000, Common chromosome aberrations in the proximal type of epithelioid sarcoma, Cancer Genet Cytogenet, 123, 133, 10.1016/S0165-4608(00)00320-4

de Vries, 1989, Epithelioid sarcoma in children and adolescents: a report of four cases, J Pediatr Surg, 24, 186, 10.1016/S0022-3468(89)80246-5

Goto, 1999, Brief report: neural differentiation of a novel cell line, YCUS-5, established from proximal-type epithelioid sarcoma of a child, Med Pediatr Oncol, 33, 137, 10.1002/(SICI)1096-911X(199908)33:2137::AID-MPO183.0.CO;2-N

Lualdi, 2004, Molecular cytogenetic characterization of proximal-type epithelioid sarcoma, Genes Chromosomes Cancer, 41, 283, 10.1002/gcc.20086

Quezado, 1998, Allelic loss on chromosome 22q in epithelioid sarcomas, Hum Pathol, 29, 604, 10.1016/S0046-8177(98)80010-5

Modena, 2005, SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas, Cancer Res, 65, 4012, 10.1158/0008-5472.CAN-04-3050

Kalpana, 1994, Binding and stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5, Science, 266, 2002, 10.1126/science.7801128

Wang, 2014, Molecular pathways: SWI/SNF (BAF) complexes are frequently mutated in cancer – mechanisms and potential therapeutic insights, Clin Cancer Res, 20, 21, 10.1158/1078-0432.CCR-13-0280

Reisman, 2009, The SWI/SNF complex and cancer, Oncogene, 28, 1653, 10.1038/onc.2009.4

Wöhrle, 2013, Fibroblast growth factor receptors as novel therapeutic targets in SNF5-deleted malignant rhabdoid tumors, PLoS One, 8, e77652, 10.1371/journal.pone.0077652

Mora Blanco, 2014, Activation of β-catenin/TCF targets following loss of the tumor suppressor SNF5, Oncogene, 33, 933, 10.1038/onc.2013.37

Medjkane, 2004, The tumor suppressor hSNF5/INI1 modulates cell growth and actin cytoskeleton organization, Cancer Res, 64, 3406, 10.1158/0008-5472.CAN-03-3004

Oruetxebarria, 2004, P16INK4a is required for hSNF5 chromatin remodeler-induced cellular senescence in malignant rhabdoid tumor cells, J Biol Chem, 279, 3807, 10.1074/jbc.M309333200

Zhang, 2002, Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5, Mol Cell Biol, 22, 5975, 10.1128/MCB.22.16.5975-5988.2002

Jagani, 2010, Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway, Nat Med, 16, 1429, 10.1038/nm.2251

Brenca, 2013, SMARCB1/INI1 genetic inactivation is responsible for tumorigenic properties of epithelioid sarcoma cell line VAESBJ, Mol Cancer Ther, 12, 1060, 10.1158/1535-7163.MCT-13-0005

Lee, 2012, A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers, J Clin Invest, 122, 2983, 10.1172/JCI64400

Klochendler Yeivin, 2006, Increased DNA damage sensitivity and apoptosis in cells lacking the Snf5/Ini1 subunit of the SWI/SNF chromatin remodeling complex, Mol Cell Biol, 26, 2661, 10.1128/MCB.26.7.2661-2674.2006

Isakoff, 2005, Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation, Proc Natl Acad Sci U S A, 102, 17745, 10.1073/pnas.0509014102

Wang, 2009, Oncogenesis caused by loss of the SNF5 tumor suppressor is dependent on activity of BRG1, the ATPase of the SWI/SNF chromatin remodeling complex, Cancer Res, 69, 8094, 10.1158/0008-5472.CAN-09-0733

Hornick, 2009, Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma, Am J Surg Pathol, 33, 542, 10.1097/PAS.0b013e3181882c54

Kohashi, 2009, Infrequent SMARCB1/INI1 gene alteration in epithelioid sarcoma: a useful tool in distinguishing epithelioid sarcoma from malignant rhabdoid tumor, Hum Pathol, 40, 349, 10.1016/j.humpath.2008.08.007

Le Loarer, 2014, Consistent SMARCB1 homozygous deletions in epithelioid sarcoma and in a subset of myoepithelial carcinomas can be reliably detected by FISH in archival material, Genes Chromosomes Cancer, 53, 475, 10.1002/gcc.22159

Papp, 2013, SMARCB1 protein and mRNA loss is not caused by promoter and histone hypermethylation in epithelioid sarcoma, Mod Pathol, 26, 393, 10.1038/modpathol.2012.190

Sullivan, 2013, Epithelioid sarcoma is associated with a high percentage of SMARCB1 deletions, Mod Pathol, 26, 385, 10.1038/modpathol.2012.175

Papp, 2014, SMARCB1 expression in epithelioid sarcoma is regulated by miR-206, miR-381, and miR-671-5p on Both mRNA and protein levels, Genes Chromosomes Cancer, 53, 168, 10.1002/gcc.22128

Kohashi, 2014, Differential microRNA expression profiles between malignant rhabdoid tumor and epithelioid sarcoma: miR193a-5p is suggested to downregulate SMARCB1 mRNA expression, Mod Pathol, 27, 832, 10.1038/modpathol.2013.213

Vivanco, 2002, The phosphatidylinositol 3-Kinase AKT pathway in human cancer, Nat Rev Cancer, 2, 489, 10.1038/nrc839

Darr, 2014, Loss of IGFBP7 expression and persistent AKT activation contribute to SMARCB1/Snf5-mediated tumorigenesis, Oncogene, 33, 3024, 10.1038/onc.2013.261

Imura, 2014, Combined targeting of mTOR and c-MET signaling pathways for effective management of epithelioid sarcoma, Mol Cancer, 13, 185, 10.1186/1476-4598-13-185

Xie, 2011, Combining EGFR and mTOR blockade for the treatment of epithelioid sarcoma, Clin Cancer Res, 17, 5901, 10.1158/1078-0432.CCR-11-0660

Lim, 2015, Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer, J Cancer Res Clin Oncol, 141, 671, 10.1007/s00432-014-1803-3

Sibilia, 2007, The epidermal growth factor receptor: from development to tumorigenesis, Differentiation, 75, 770, 10.1111/j.1432-0436.2007.00238.x

Dobashi, 2004, Aberration of epidermal growth factor receptor expression in bone and soft-tissue tumors: protein overexpression, gene amplification and activation of downstream molecules, Mod Pathol, 17, 1497, 10.1038/modpathol.3800218

Dobashi, 2007, Involvement of epidermal growth factor receptor and downstream molecules in bone and soft tissue tumors, Hum Pathol, 38, 914, 10.1016/j.humpath.2006.12.005

Bode, 2006, Mutations in the tyrosine kinase domain of the EGFR gene are rare in synovial sarcoma, Mod Pathol, 19, 541, 10.1038/modpathol.3800560

Tawbi, 2008, Epidermal growth factor receptor expression and mutational analysis in synovial sarcomas and malignant peripheral nerve sheath tumors, Oncologist, 13, 459, 10.1634/theoncologist.2007-0166

Cascio, 2010, Epithelioid sarcoma expresses epidermal growth factor receptor but gene amplification and kinase domain mutations are rare, Mod Pathol, 23, 574, 10.1038/modpathol.2010.2

Ino, 2002, Dysadherin, a cancer-associated cell membrane glycoprotein, down-regulates E-cadherin and promotes metastasis, Proc Natl Acad Sci U S A, 99, 365, 10.1073/pnas.012425299

Nam, 2006, Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells, Cancer Res, 66, 7176, 10.1158/0008-5472.CAN-06-0825

Park, 2011, Dysadherin can enhance tumorigenesis by conferring properties of stem-like cells to hepatocellular carcinoma cells, J Hepatol, 54, 122, 10.1016/j.jhep.2010.06.026

Izumi, 2006, Prognostic significance of dysadherin expression in epithelioid sarcoma and its diagnostic utility in distinguishing epithelioid sarcoma from malignant rhabdoid tumor, Mod Pathol, 19, 820, 10.1038/modpathol.3800599

Lee, 2012, Dysadherin expression promotes the motility and survival of human breast cancer cells by AKT activation, Cancer Sci, 103, 1280, 10.1111/j.1349-7006.2012.02302.x

Behrens, 2000, Control of beta-catenin signaling in tumor development, Ann N Y Acad Sci, 910, 21, 10.1111/j.1749-6632.2000.tb06698.x

Sakharpe, 2011, Epithelioid sarcoma and unclassified sarcoma with epithelioid features: clinicopathological variables, molecular markers, and a new experimental model, Oncologist, 16, 512, 10.1634/theoncologist.2010-0174

Saito, 2001, Expression of intercellular adhesion molecules in epithelioid sarcoma and malignant rhabdoid tumor, Pathol Int, 51, 532, 10.1046/j.1440-1827.2001.01232.x

van Roy, 2008, The cell-cell adhesion molecule E-cadherin, Cell Mol Life Sci, 65, 3756, 10.1007/s00018-008-8281-1

Tian, 2011, E-cadherin/β-catenin complex and the epithelial barrier, J Biomed Biotechnol, 2011, 567305, 10.1155/2011/567305

Wu, 2008, New insights of epithelial-mesenchymal transition in cancer metastasis, Chin J Biochem Biophys, 40, 643, 10.1111/j.1745-7270.2008.00443.x

Bast, 1983, A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer, N Engl J Med, 309, 883, 10.1056/NEJM198310133091503

Kato, 2004, CA125 expression in epithelioid sarcoma, Jpn J Clin Oncol, 34, 149, 10.1093/jjco/hyh027

Hoshino, 2010, Serum CA 125 expression as a tumor marker for diagnosis and monitoring the clinical course of epithelioid sarcoma, J Cancer Res Clin Oncol, 136, 457, 10.1007/s00432-009-0678-1

Sabbatini, 2013, Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO – the MIMOSA study, J Clin Oncol, 31, 1554, 10.1200/JCO.2012.46.4057

Buzzonetti, 2014, Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival-a substudy of the MIMOSA trial, Cancer Immunol Immunother, 63, 1037, 10.1007/s00262-014-1569-0

Roché, 1993, Characterization and chemosensitivity of a human epithelioid sarcoma cell line (SARCCR 2), Int J Cancer, 54, 663, 10.1002/ijc.2910540423

Reinecke, 2000, Growth inhibitory effects of paclitaxel on human epithelioid sarcoma in vitro: heterogeneity of response and the multidrug resistance phenotype, Cancer, 88, 1614, 10.1002/(SICI)1097-0142(20000401)88:71614::AID-CNCR163.0.CO;2-X

Kusakabe, 2000, Expression of lung resistance protein in epithelioid sarcoma in vitro and in vivo, Arch Dermatol Res, 292, 292, 10.1007/s004030000127

Penot, 2013, Stabilization of multiple metastatic epithelioid sarcoma under treatment with sunitinib malate, Br J Dermatol, 168, 871, 10.1111/bjd.12038

van der Graaf, 2012, Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial, Lancet, 379, 1879, 10.1016/S0140-6736(12)60651-5

Sokolowski, 2014, Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma, Oncogene, 33, 1877, 10.1038/onc.2013.129

Lin, 2005, Expression profile and molecular genetic regulation of cyclin D1 expression in epithelioid sarcoma, Mod Pathol, 18, 705, 10.1038/modpathol.3800349

Lee, 2004, Comparative genomic hybridization in epithelioid sarcoma, Br J Dermatol, 151, 1054, 10.1111/j.1365-2133.2004.06246.x

Orrock, 2009, INI1 and GLUT-1 expression in epithelioid sarcoma and its cutaneous neoplastic and nonneoplastic mimics, Am J Dermatopathol, 31, 152, 10.1097/DAD.0b013e31818a5c4f

Raoux, 2009, Primary epithelioid sarcoma of bone: report of a unique case, with immunohistochemical and fluorescent in situ hybridization confirmation of INI1 deletion, Am J Surg Pathol, 33, 954, 10.1097/PAS.0b013e31819b92d5

Kohashi, 2014, ERG and SALL4 expressions in SMARCB1/INI1-deficient tumors: a useful tool for distinguishing epithelioid sarcoma from malignant rhabdoid tumor, Hum Pathol, 46, 225, 10.1016/j.humpath.2014.10.010

Stockman, 2014, ERG and FLI1 protein expression in epithelioid sarcoma, Mod Pathol, 27, 496, 10.1038/modpathol.2013.161

Miettinen, 2013, ERG expression in epithelioid sarcoma: a diagnostic pitfall, Am J Surg Pathol, 37, 1580, 10.1097/PAS.0b013e31828de23a

Li, 2014, Concurrent loss of INI1, PBRM1, and BRM expression in epithelioid sarcoma: implications for the cocontributions of multiple SWI/SNF complex members to pathogenesis, Hum Pathol, 45, 2247, 10.1016/j.humpath.2014.06.027

Kusakabe, 1994, Metastatic epithelioid sarcoma with an N-ras oncogene mutation, Am J Dermatopathol, 16, 294, 10.1097/00000372-199406000-00012

de Torres, 2005, Epithelioid sarcoma with SYT-SSX1 fusion gene expression: molecular and cytogenetic analysis, Cancer Genet Cytogenet, 162, 50, 10.1016/j.cancergencyto.2005.03.009

Gerharz, 2000, Analysis of growth factor-dependent signalling in human epithelioid sarcoma cell lines: clues to the role of autocrine, juxtacrine and paracrine interactions in epithelioid sarcoma, Eur J Cancer, 36, 1171, 10.1016/S0959-8049(00)00053-8

Kusakabe, 1997, Establishment and characterization of an epithelioid sarcoma cell line with an autocrine response to interleukin-6, Arch Dermatol Res, 289, 224, 10.1007/s004030050184

Braverman, 1995, Hemin toxicity in a human epithelioid sarcoma cell line, Anticancer Res, 15, 1963

Engers, 1999, In vitro invasiveness of human epithelioid-sarcoma cell lines: association with cell motility and inverse correlation with the expression of tissue inhibitor of metalloproteinases, Int J Cancer, 80, 406, 10.1002/(SICI)1097-0215(19990129)80:3406::AID-IJC123.0.CO;2-L

Engers, 1996, Growth inhibition in clonal subpopulations of a human epithelioid sarcoma cell line by retinoic acid and tumour necrosis factor alpha, Br J Cancer, 73, 491, 10.1038/bjc.1996.86

Emori, 2013, High expression of CD109 antigen regulates the phenotype of cancer stem-like cells/cancer-initiating cells in the novel epithelioid sarcoma cell line ESX and is related to poor prognosis of soft tissue sarcoma, PLoS One, 8, e84187, 10.1371/journal.pone.0084187

Reeves, 1987, Ultrastructural, immunocytochemical, and cytogenetic characterization of a human epithelioid sarcoma cell line (RM-HS1), J Natl Cancer Inst, 78, 7, 10.1093/jnci/78.1.7

Kelland, 1988, Radiosensitivity and characterisation of a newly established cell line from an epithelioid sarcoma, Br J Cancer, 58, 322, 10.1038/bjc.1988.211

Gerharz, 1990, Multidirectional differentiation in a newly established human epithelioid sarcoma cell line (GRU-1) with co-expression of vimentin, cytokeratins and neurofilament proteins, Int J Cancer, 45, 143, 10.1002/ijc.2910450126

Sonobe, 1993, Morphological characterization of a new human epithelioid sarcoma cell line, ES020488, in vitro and in vivo, Virchows Arch B Cell Pathol, 63, 219, 10.1007/BF02899265

Helson, 1995, Va-es-bj – an epithelioid sarcoma cell-line, Int J Oncol, 7, 51

Stenman, 1990, A cell culture, chromosomal and quantitative DNA analysis of a metastatic epithelioid sarcoma. Deletion 1p, a possible primary chromosomal abnormality in epithelioid sarcoma, Cancer, 65, 2006, 10.1002/1097-0142(19900501)65:92006::AID-CNCR28206509213.0.CO;2-Q

Nishio, 2005, Establishment of a new human epithelioid sarcoma cell line, FU-EPS-1: molecular cytogenetic characterization by use of spectral karyotyping and comparative genomic hybridization, Int J Oncol, 27, 361, 10.3892/ijo.27.2.361

Imura, 2013, A novel angiomatoid epithelioid sarcoma cell line, Asra-EPS, forming tumors with large cysts containing hemorrhagic fluid in vivo, BMC Res Notes, 6, 305, 10.1186/1756-0500-6-305